Featured Research

from universities, journals, and other organizations

Gene may help predict best chemotherapy treatment for pancreatic cancer patients

Date:
February 5, 2013
Source:
Moffitt Cancer Center
Summary:
Researchers have identified a gene that may better predict survival for pancreatic adenocarcinoma, the fourth leading cause of cancer deaths in the United States. The scientists conducted a study that better defines the role of ribonucleotide reductase M1 (RRM1). The RRM1 gene encodes the regulatory subunit of ribonucleotide reductase, the molecular target of gemcitabine, a commonly used chemotherapy in pancreatic cancer.

Moffitt Cancer Center researchers have identified a gene that may better predict survival for pancreatic adenocarcinoma, the fourth leading cause of cancer deaths in the United States. Researcher Richard Kim, M.D., assistant member of the Experimental Therapeutics Program and colleagues from several other research institutions conducted a study that better defines the role of ribonucleotide reductase M1 (RRM1). The RRM1 gene encodes the regulatory subunit of ribonucleotide reductase, the molecular target of gemcitabine, a commonly used chemotherapy in pancreatic cancer.

In the study, which appeared in the Jan. 1 issue of Cancer, the research team investigated the therapeutic predictive value of RRM1 expression for the chemotherapy drug gemcitabine. They found that for patients with pancreatic adenocarcinoma removed by surgery, low RRM1 expression predicted an overall survival benefit with gemcitabine therapy. High RRM1 expression predicted benefit from non-gemcitabine therapy.

"We previously hypothesized that low expression of RRM1 could predict the treatment success of gemcitabine," Kim said. "This study was carried out to determine whether RRM1 expression correlates with better survival for patients receiving gemcitabine therapy."

The retrospective study included 122 patients who had undergone surgery for pancreatic adenocarcinoma from 1999 to 2007. In the subgroup of patients who received gemcitabine therapy, those with low RRM1 expression had longer overall survival and a trend toward progression-free survival. Those patients with high RRMI expression who received non-gemcitabine therapy had significantly longer overall survival and progression-free survival.

"Our findings indicate that to achieve the best survival after surgical resection, the level of RRM1 expression may be used to select which patients receive gemcitabine therapy and which do not," Kim said.

The authors noted that their findings were consistent with similar studies on the role RRM1 plays in chemotherapy for patients with non-small cell lung cancer, yet their conclusions "should be interpreted with caution" due to their small sample size and the therapeutic success of non-gemcitabine therapies after surgery.

"A validation study should be carried out before the current findings can be clinically applied," Kim added.

Kim worked with researchers from Cleveland Clinic, Case Western Reserve University School of Medicine, Veridex, LLC, and Johnson & Johnson Company on this study.


Story Source:

The above story is based on materials provided by Moffitt Cancer Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Hao Xie, Wei Jiang, John Jiang, Yixin Wang, Richard Kim, Xiaobo Liu, Xiuli Liu. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer, 2013; 119 (1): 173 DOI: 10.1002/cncr.27715

Cite This Page:

Moffitt Cancer Center. "Gene may help predict best chemotherapy treatment for pancreatic cancer patients." ScienceDaily. ScienceDaily, 5 February 2013. <www.sciencedaily.com/releases/2013/02/130205123437.htm>.
Moffitt Cancer Center. (2013, February 5). Gene may help predict best chemotherapy treatment for pancreatic cancer patients. ScienceDaily. Retrieved April 16, 2014 from www.sciencedaily.com/releases/2013/02/130205123437.htm
Moffitt Cancer Center. "Gene may help predict best chemotherapy treatment for pancreatic cancer patients." ScienceDaily. www.sciencedaily.com/releases/2013/02/130205123437.htm (accessed April 16, 2014).

Share This



More Health & Medicine News

Wednesday, April 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Outbreak Now Linked To 121 Deaths

Ebola Outbreak Now Linked To 121 Deaths

Newsy (Apr. 15, 2014) The ebola virus outbreak in West Africa is now linked to 121 deaths. Health officials fear the virus will continue to spread in urban areas. Video provided by Newsy
Powered by NewsLook.com
Cognitive Function: Is It All Downhill From Age 24?

Cognitive Function: Is It All Downhill From Age 24?

Newsy (Apr. 15, 2014) A new study out of Canada says cognitive motor performance begins deteriorating around age 24. Video provided by Newsy
Powered by NewsLook.com
How Mt. Everest Helped Scientists Research Diabetes

How Mt. Everest Helped Scientists Research Diabetes

Newsy (Apr. 15, 2014) British researchers were able to use Mount Everest's low altitudes to study insulin resistance. They hope to find ways to treat diabetes. Video provided by Newsy
Powered by NewsLook.com
Carpenter's Injury Leads To Hundreds Of 3-D-Printed Hands

Carpenter's Injury Leads To Hundreds Of 3-D-Printed Hands

Newsy (Apr. 14, 2014) Richard van As lost all fingers on his right hand in a woodworking accident. Now, he's used the incident to create a prosthetic to help hundreds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins